{
  "id": "6cca02cd916946bb",
  "title": "RO CEO on The Rise of GLP-1 Drugs",
  "description": "Zach Reitano, CEO of RO, says demand for the company\u2019s pill has far exceeded expectations. He tells Romaine Bostick and Katie Greifeld on \u201cThe Close\u201d that the oral medication is more approachable and affordable, noting the price has dropped from about $1,300 eight months ago to a starting price of $149. (Source: Bloomberg)",
  "content": "Zach Reitano, CEO of RO, says demand for the company\u2019s pill has far exceeded expectations. He tells Romaine Bostick and Katie Greifeld on \u201cThe Close\u201d that the oral medication is more approachable and affordable, noting the price has dropped from about $1,300 eight months ago to a starting price of $149. (Source: Bloomberg)",
  "source": "Bloomberg Markets",
  "source_url": "https://www.bloomberg.com/news/videos/2026-01-29/ro-ceo-on-the-rise-of-glp-1-drugs-video",
  "published_at": "2026-01-29T22:45:54+00:00",
  "fetched_at": "2026-01-30T00:27:47.504790+00:00",
  "category": "macroeconomics_finance",
  "subcategory": null,
  "keywords": [
    "ai",
    "drug"
  ],
  "location": null,
  "raw_data": {
    "title": "RO CEO on The Rise of GLP-1 Drugs",
    "description": "Zach Reitano, CEO of RO, says demand for the company\u2019s pill has far exceeded expectations. He tells Romaine Bostick and Katie Greifeld on \u201cThe Close\u201d that the oral medication is more approachable and affordable, noting the price has dropped from about $1,300 eight months ago to a starting price of $149. (Source: Bloomberg)",
    "url": "https://www.bloomberg.com/news/videos/2026-01-29/ro-ceo-on-the-rise-of-glp-1-drugs-video",
    "published": "2026-01-29T22:45:54+00:00",
    "source": "Bloomberg Markets"
  }
}